Document Detail


Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.
MedLine Citation:
PMID:  20922537     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Enalapril is effective in the suppression of left ventricular remodeling after acute myocardial infarction (AMI), but the effect of telmisartan is unclear. The consecutive 163 AMI patients underwent primary percutaneous coronary intervention and were randomized to telmisartan (n = 82) or enalapril (n = 81). Left ventriculography was performed in the acute and chronic (6 months) phases. Matrix metalloproteinase (MMP)-2 and MMP-9 activities were measured by zymography in the acute (days 1, 7, and 14) and chronic (6 months) phases. Plasma pentraxin3 (PTX3), a marker of vascular inflammation, was also measured. There were no adverse effects in the telmisartan group. The analysis of the left ventriculograms in the acute and chronic phases revealed no difference between the two groups. MMP-9 activities at days 7 and 14 and in the chronic phase were decreased compared to that at day 1 in both groups. MMP-2 activity was also decreased in the acute phase, but increased in the chronic phase in both groups. There was no difference in the plasma PTX3 level in the acute phase, but in the chronic phase, PTX3 was significantly lower in telmisartan than in enalapril group (2.6 ± 1.4 vs. 3.2 ± 1.6 ng/ml, p = 0.04). Telmisartan is well tolerated, shows similar effects on the markers of left ventricular remodeling to those of enalapril, and suppresses vascular inflammation more effectively than enalapril in AMI patients. Telmisartan can be an alternative to angiotensin converting enzyme inhibitor in patients with AMI.
Authors:
Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Related Documents :
20082877 - Extracellular matrix metalloproteinase inducer (emmprin) is increased in human left ven...
12906367 - Hypothalamo-pituitary-adrenal axis in acute myocardial infarction treated by percutaneo...
20593417 - Acute myocardial infarction and anorexia nervosa.
11506297 - Long-term prognosis after recovery from myocardial infarction: a community-based survey...
17056317 - Usefulness of aspirin resistance after percutaneous coronary intervention for acute myo...
22740087 - Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2010-10-05
Journal Detail:
Title:  Heart and vessels     Volume:  25     ISSN:  1615-2573     ISO Abbreviation:  Heart Vessels     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-08     Completed Date:  2011-02-25     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  8511258     Medline TA:  Heart Vessels     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  460-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Biological Markers / blood
C-Reactive Protein / metabolism
Chi-Square Distribution
Enalapril / therapeutic use*
Female
Humans
Inflammation Mediators / metabolism
Japan
Male
Matrix Metalloproteinase 2 / blood
Matrix Metalloproteinase 9 / blood
Middle Aged
Myocardial Infarction / drug therapy*,  metabolism,  physiopathology,  radiography
Prospective Studies
Serum Amyloid P-Component / metabolism
Stroke Volume / drug effects
Time Factors
Treatment Outcome
Ventricular Function, Left / drug effects
Ventricular Remodeling / drug effects*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzimidazoles; 0/Benzoates; 0/Biological Markers; 0/Inflammation Mediators; 0/Serum Amyloid P-Component; 148591-49-5/PTX3 protein; 69PN84IO1A/Enalapril; 9007-41-4/C-Reactive Protein; EC 3.4.24.24/MMP2 protein, human; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of graft adaptation of the internal mammary artery on longitudinal phasic blood flow velocity...
Next Document:  Treatment effects of renin-angiotensin system inhibitor and calcium channel blocker in patients with...